 JERSEY CITY, N.J., Feb. 23, 2021 GLOBE NEWSWIRE -- SCYNEXIS, Inc. NASDAQ: SCYX, a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced it has partnered with Amplity Health in connection with the anticipated U.S. launch of Brexafemme ibrexafungerp. Amplity, a leading global contract commercialization organization, specializes in designing, implementing, and managing customer facing and inside sales, service, medical and clinical teams. Brexafemme is the expected trade name for ibrexafungerp, an oral antifungal product candidate for the treatment of vulvovaginal candidiasis VVC, also known as vaginal yeast infection. The New Drug Application NDA for Brexafemme is under review by the U.S. Food and Drug Administration FDA with a Prescription Drug User Fee Act PDUFA action date of June 1, 2021. If approved, Brexafemme would represent the first novel antifungal class in over 20 years and would be the first and only non-azole treatment for vaginal yeast infections. 